The Finnish Orion Pharma has begun the liquidation of the Russian office – it is planned to close it before the end of 2022.
Vedomosti writes about this, citing a source familiar with the company’s plans.
According to the interlocutor, layoffs of employees of the local division are now continuing. This information is confirmed by a source close to the top management of the OP.
The newspaper notes that there are no open vacancies from the Finnish company on the largest recruiting services HeadHunter and SuperJob.
Orion Pharma has been operating in Russia for 15 years. In 2021, the company ranked 98th in the ranking of the largest pharmaceutical companies, according to DSM Group. In 2022, she rose to 90th place.
The revenue of the Russian division of the company for 2021 reached 4.7 billion rubles, an increase of 45% compared to the previous year. Net profit for the same period amounted to 121.6 million rubles. against 129.7 million rubles. a year earlier.
The main drug of the company is metipred, intended for the treatment of rheumatoid arthritis.